A nonprofit organization dedicated to studying the U.S. drug patent system released a new approach on Tuesday, focused on confronting the practices of pharmaceutical companies that reportedly employ patent thickets to inflate the prices of prescription drugs. The use of patent thickets – a web of overlapping intellectual property rights that a company takes up to prevent competitors from easily entering the market – is a contentious issue in the pharmaceutical industry.
As the name suggests, patent thickets can create a complicated landscape for potential market newcomers, effectively establishing a shield around the holder’s product. In the pharmaceutical domain, critics argue that this technique is regularly leveraged to drive up the costs of prescription drugs.
The group’s blueprint could mark a significant step towards addressing this industry issue, although the details of their proposed plan remain undisclosed. Understanding and combating practices associated with patent thickets could potentially foster a more competitive market and consequently prevent disproportionate drug pricing.
Examine this issue further in the original Law360 article.